GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Xizang Weixinkang Pharmaceutical Co Ltd (SHSE:603676) » Definitions » Debt-to-Equity

Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Debt-to-Equity : 0.00 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Xizang Weixinkang Pharmaceutical Co Debt-to-Equity?

Xizang Weixinkang Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥2 Mil. Xizang Weixinkang Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥2 Mil. Xizang Weixinkang Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2025 was ¥1,470 Mil. Xizang Weixinkang Pharmaceutical Co's debt to equity for the quarter that ended in Mar. 2025 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Xizang Weixinkang Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

During the past 12 years, the highest Debt-to-Equity Ratio of Xizang Weixinkang Pharmaceutical Co was 0.08. The lowest was 0.00. And the median was 0.01.

SHSE:603676's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

Xizang Weixinkang Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Xizang Weixinkang Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xizang Weixinkang Pharmaceutical Co Debt-to-Equity Chart

Xizang Weixinkang Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 -

Xizang Weixinkang Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 0.01 - -

Competitive Comparison of Xizang Weixinkang Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Xizang Weixinkang Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xizang Weixinkang Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Xizang Weixinkang Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Xizang Weixinkang Pharmaceutical Co's Debt-to-Equity falls into.


;
;

Xizang Weixinkang Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Xizang Weixinkang Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Xizang Weixinkang Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xizang Weixinkang Pharmaceutical Co  (SHSE:603676) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Xizang Weixinkang Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Xizang Weixinkang Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Xizang Weixinkang Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Yuanqu South Road, 3rd Floor, Building 4, Industrial Center, No. 5, Zone B, Lhasa Economic and Technological, Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
Executives
Weng Zi Zhong senior management
Chen Shi Gong Directors, senior managers
Zhou Xiao Bing senior management
Liu Feng Directors, senior managers
Yu Hai Bo senior management
Zhang Hong Directors, senior managers
Zheng Yan Xia senior management
Wen Xiao Quan Director

Xizang Weixinkang Pharmaceutical Co Headlines

No Headlines